(S,R,S)-AHPC-C1-Br

Cat. No.:	HY-138862
CAS No.:	2379404-33-6
Molecular Formula:	$C_{24}H_{31}BrN_4O_4S$
Molecular Weight:	551.5
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (226.65 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8132 mL	9.0662 mL	18.1324 mL
	5 mM	0.3626 mL	1.8132 mL	3.6265 mL
	10 mM	0.1813 mL	0.9066 mL	1.8132 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

(S,R,S)-AHPC-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology[1].

IC_{50} & Target

VHL

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. Comput Struct Biotechnol J. 2019;17:160-176. Published 2019 Jan 25.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA